A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, William Fraser Symmans, Ben Ho Park, Brian Leslie Burnette, Amye Juliet Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Erica L. Mayer, William M. Sikov, Eve T. Rodler, Lynne I. Wagner, Angela DeMichele, Joseph A. Sparano, Antonio C. Wolff, Kathy Miller
Institutions: Vanderbilt University, Dana-Farber Cancer Institute, Vanderbilt-Ingram Cancer Center, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Michigan Cancer Research Consortium, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Northwestern University, Women & Infants Hospital of Rhode Island, Wake Forest University Health Sciences, Wake Forest University, Abramson Cancer Center, University of Pennsylvania, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4205782152